Member Info for whimax

This is all the Bot doing this. Pulling down to let Shorts close.
How low tho? That’s the question!

Exactly JH.

YOU MUST HOLD SHARES IN AN ACCOUNT AT 7am ON 30th OCTOBER IN ORDER TO GET AccuStem Shares!!

That is all.

If those selling today are seriously expecting to still qualify for AccuStem shares, they are in for a HUUUUGE disappointment lol.
You MUST hold shares in your account at 7am on 31th October.

Hope everyone got some cheap ones this morning?

Indeed Davey, so these warrants (converted today) will still get on the register in time? Looks like we have another day to get in?

Not convinced we’ve seen the last of the nonsense tbh. If that RNS this afternoon confused us in the UK, you can’t begin to imagine what it’s done to ouR American friends lol.
Wouldn’t surprise me in the slightest if this went crazy tomorrow afternoon. Also, there’s an element of understanding on here (LSE) regarding what the score is with cut off dates etc, but do investors on iii etc (where there’s virtually zero chat) honestly get Record Dates, T+2’s etc? I’m not 100% sure!!.

Wait till you see today’s ones tomorrow lol.

Check out the delayed trades coming through from yesterday lol. How have they managed to keep this at this level this week?? Incredibly!!

P.s. Anyone who hasn’t bought by now, or who plans to sell before Friday and thinks they will still qualify for AccuStem shares is off their trolly imo. I don’t care what individual brokers say (you might get lucky and might come off for you) but if that’s your strategy, you’ve taken a massive unnecessary risk.
I had planned to top slice a few (as I’m sure a few other s have, but this is now is a “hold everything” and take as many AccuStem shares as I can. If it drops further i might even add more on a spread bet, because from this level, any drop will be short and minimal.

Having said all of the above, we might still get fireworks tomorrow.

GL all.

Lol. Shorters could be in trouble lol. Best get those closed and get them back to their rightful owners!!

That’s the unknown adsman. A bid now of £200m (for example) is worth £1 a share, but given 8-12 months to develop AccuStem and obtain some market share £1b+ or £5 a share certainly isn’t out of the question.
As you’ll have seen in the interviews and RNS’s StemPrinter (based on studies already carried out) is 40% better/more accurate than the market leader (Oncotype DX) which sold for $2.8b just over a year ago, so the sky really is the limit, if it’s marketed properly.

adsman, Yes. After Demerger date, if an offer is made for AccuStem before it lists, it would be voted on by the (would be) shareholders (i.e. those who qualify for shares on Friday) and, if voted through each share would receive an equal share of the offer price.

jmfw, I take your point, but I think there are just too many unknowns for them. I think they think they are currently safe in the knowledge that the BoD won’t drop any news now till after the Cut Off. At any point from Friday tho, we could get Foralumab Trial update, Main Market move, Foralumab inhaler patent news, or even a collaboration from left field, which the BoD might use to prevent any sell off. I just think that’s too risky for Shorters (even with the bot helping them).

Also, with regards AccuStem, whoever owns the shares being used to Short are unlikely to accept Book Value of £4m as payment for missing out on AccuStem. I’m expecting a minimum of £1 a share for AccuStem by the time it lists, and then of course there’s the possibility that it won’t list at all, and is just being packaged up for a buyer to walk away with, before it hits the market.

Finally, if they are Short, they will have no way of getting hold of shares in AccuStem to give to share owners until it actually list, at which point the price could be anything.

This is the time to top up if you are going to. Once Shorts have been let off (again) this will move up quickly.

This is the drag down to let Shorts close imo.

HOLD! DON’T PANIC.

Nelson, to be blunt, No, you have it completely wrong I’m afraid.
If you borrow shares to Short, you are effectively selling them, so neither the Shorter nor the original owner currently own the shares.
The Shorter, at some point has to buy the shares back and return them to the original owner (with interest). The original owner, in this scenario will have to have the shares back in their dealing account by CoB on 29th October in order to qualify for AccuStem shares.
If the Shorter does not buy them back and return them to the original owner by that date then the Shorter is liable to the original owner for the original shares, plus interest, plus the value of the loss for missing out on the AccuStem shares.

LegalWolf. If you are Short, you will not qualify for AccuStem as you have effectively sold shares you do not own.

Not sure I’m with you Nelson. Whoever “owns” the shares that the Shorters have “borrowed” will miss out on the AccuStem shares if they are not returned by Cut Off date. Shorters will be liable to the owner for the value of that missed opportunity.

I get that Soup, and thanks for sharing. My response was more in respect of the other replies tbh.

What are your thoughts on final paragraph?

Like everything, there are 2 ways to look at this (negatively or positively) I guess. Firstly this doesn’t sound like a deal that would in any way be relevant to NFX as payments are TO Kissei and not the other way round, and secondly, you can look on it as Kissei now being back open for business.
The last paragraph, is also interesting, although I’m not 100% sure what it means.

Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines). Kissei receives from Affamed an upfront payment, and will be eligible to receive development milestone payments according to stages of development and royalty payments according to the sales of product.

KDT-3594 is a novel orally administrable non-ergot dopamine agonist, which acts by stimulating dopamine receptors in the basal ganglia, thereby ameliorating the symptoms of Parkinson's Disease caused by insufficient action of dopamine. It is also confirmed as a new therapeutic agent for Parkinson's disease that KDT-3594 reduces the risk of the characteristic side effects of existing ergot and non-ergot dopamine agonists. KDT-3594 is currently under Phase 2 clinical trials in Japan.

Kissei focuses on drug discovery, research and development of new drugs, and aims at international expansion by licensing out strategy. One of the policies of PEGASUS, 5-year medium-term management plan launched in April 2020, is to strengthen earnings base overseas. In collaboration with partner companies, Kissei will contribute to the health of people around the world through developing novel drugs.

The financial effects on Kissei's consolidated business forecasts of the fiscal year ending in March 2021 by this agreement is currently under scrutiny, and will be announced at the time of the announcement of the financial results of the second quarter of the fiscal year ended in March 2021, scheduled on November 5, 2020.

Well someone is pretty confident, having dropped £28k in at the highest price of the day. 550,000 at 5.10p isn’t chump change.